A core problem across all six is that they are mostly **intervention hypotheses**, not direct **mechanistic loop hypotheses**. The gap asks what molecular feedback loops *sustain* the oxidative stress to cell-death cycle. Several proposals identify plausible breakpoints, but they do not cleanly specify the recursive loop architecture, cell-type specificity, or temporal ordering needed to explain self-amplification.
## Hypothesis 1: NRF2 restoration
**Weak links**
- It treats NRF2 failure as a master upstream defect, but in many stressed neurons NRF2 suppression may be **secondary** to mitochondrial collapse, chromatin changes, proteostasis failure, or cell-type-specific limits in transcriptional reserve.
- NRF2 activation is broad and pleiotropic; rescue would not prove NRF2 is the core perpetuating loop.
- Dopaminergic neuron death in PD may be driven by compartments where transcriptional rescue is too slow relative to acute mitochondrial ROS, calcium overload, or lipid peroxidation.
**Counter-evidence / alternative explanations**
- Chronic NRF2 activation can be incomplete or maladaptive; some antioxidant programs shift iron handling, heme metabolism, and metabolic state in ways that do not necessarily improve survival.
- Neuronal NRF2 responses are often weaker than astrocytic ones, so observed protection may be mostly **non-cell-autonomous**.
- Oxidative stress in PD may be driven more by dopamine oxidation, iron chemistry, defective mitophagy, or neuroinflammation than by insufficient ARE output per se.
**Falsifying experiment**
- Use neuron-specific versus astrocyte-specific NRF2 gain-of-function in a PD-relevant model, with time-resolved measures of ROS, mitochondrial membrane potential, lipid peroxidation, and death-pathway activation.
- If NRF2 restoration normalizes target genes but does **not** stop ROS re-escalation or death-pathway engagement, NRF2 is not the master breakpoint.
**Revised confidence**
- **0.58**
## Hypothesis 2: NAD+ repletion / PARP-parthanatos
**Weak links**
- This is one of the more coherent feedback-loop hypotheses, but it may over-privilege **DNA damage/PARP1** relative to other dominant ROS-death couplings.
- Exogenous NAD+ precursors do not guarantee correction of the relevant intracellular or mitochondrial NAD+ pools.
- Parthanatos may be important in some toxin models yet not dominant across idiopathic PD biology.
**Counter-evidence / alternative explanations**
- NAD+ boosting can improve mitochondrial function even if PARP is not central, so efficacy would not uniquely validate the proposed loop.
- If ETC dysfunction is primary, NAD+ supplementation may be supportive but not cycle-breaking.
- PARP inhibition can alter inflammation and transcription independently of parthanatos.
**Falsifying experiment**
- In the same model, compare PARP1 knockout, AIFM1 blockade, and NAD+ precursor treatment with direct measurements of PAR formation, AIF translocation, ATP collapse, and neuronal death.
- If NAD+ rescue occurs without suppressing PAR/AIF signaling, or if PARP/AIF blockade does not reduce ROS escalation, this loop is not dominant.
**Revised confidence**
- **0.66**
## Hypothesis 3: Mitochondrial antioxidants
**Weak links**
- It assumes mitochondrial ROS is the primary source, but ROS may come from dopamine auto-oxidation, NOX enzymes, peroxisomes, iron-catalyzed lipid oxidation, or dying-neuron inflammation.
- MitoQ accumulation depends on membrane potential; the worst-hit mitochondria may accumulate it poorly.
- Reducing ROS at one site does not explain how death pathways feed back to regenerate ROS.
**Counter-evidence / alternative explanations**
- Prior generic antioxidant failures in neurodegeneration argue that ROS scavenging alone often does not alter disease-driving circuitry.
- MitoQ/SS31 benefits may reflect membrane stabilization or bioenergetic support rather than interruption of a true ROS-death feedback loop.
- Complex I dysfunction in PD is heterogeneous; some neurons may die through alpha-synuclein, lysosomal, or calcium mechanisms not rescued by these agents.
**Falsifying experiment**
- Map ROS origin using compartment-specific probes and perturbations: mitochondrial antioxidants, NOX inhibition, iron chelation, dopamine metabolism blockade.
- If mitochondrial-targeted antioxidants lower mitochondrial ROS but not lipid peroxidation, calcium dysregulation, or death commitment, the primary-amplifier claim fails.
**Revised confidence**
- **0.49**
## Hypothesis 4: Iron chelation / ferroptosis
**Weak links**
- Strong for a subset of PD-like states, but it risks overgeneralizing **ferroptosis** as the main death-amplification engine.
- Elevated iron in substantia nigra does not establish that labile iron is the driver rather than a byproduct of degeneration or neuromelanin changes.
- Ferroptosis markers in vivo are often indirect and can overlap with other oxidative death programs.
**Counter-evidence / alternative explanations**
- Some PD models show apoptosis-, parthanatos-, or inflammation-dominant death without clear ferroptotic dependency.
- Iron chelation could help by reducing alpha-synuclein aggregation or general oxidative burden, not specifically by blocking a Fenton-ferroptosis loop.
- Chronic chelation has translational liabilities: anemia, systemic iron depletion, and possibly impaired mitochondrial enzyme function.
**Falsifying experiment**
- In vivo, compare deferiprone with ferroptosis-specific interventions such as GPX4 stabilization, ACSL4 loss, or liproxstatin rescue, while measuring labile iron, oxidized phospholipid species, and pathway-selective death markers.
- If iron lowering does not suppress ferroptosis-specific lipid signatures or if GPX4-axis rescue fails to protect, the ferroptotic loop is overstated.
**Revised confidence**
- **0.61**
## Hypothesis 5: Microglial NOX2 inhibition
**Weak links**
- This is a plausible **propagation** loop, but it may explain spread and neighborhood toxicity better than the initial intracellular vicious cycle within vulnerable neurons.
- Many PD toxin models exaggerate inflammatory contributions.
- NOX2 inhibition may miss ROS generated inside neurons before microglial engagement.
**Counter-evidence / alternative explanations**
- Microglial activation can be reactive rather than causative.
- Other immune pathways may dominate: inflammasome signaling, complement, T-cell recruitment, astrocytic reactivity.
- Dihydroethidium-style ROS readouts can be nonspecific, making causal claims shaky.
**Falsifying experiment**
- Use microglia-specific CYBB deletion versus neuron-specific mitochondrial ROS suppression in a model with staged alpha-synuclein pathology.
- If neuronal ROS and death proceed before substantial NOX2-dependent microglial activation, then NOX2 is an amplifier of spread, not the core vicious-cycle driver.
**Revised confidence**
- **0.57**
## Hypothesis 6: SIRT3 activation
**Weak links**
- Mechanistically plausible but underspecified as a self-amplifying loop; it is more a **mitochondrial resilience modifier** than an identified recursion.
- SIRT3 pharmacology is muddy; compounds like honokiol have multiple targets.
- Dependence on NAD+ means SIRT3 may collapse downstream of the same bioenergetic failure it is supposed to correct.
**Counter-evidence / alternative explanations**
- Benefits from SIRT3 activators may come from broader anti-inflammatory or mitochondrial effects unrelated to SIRT3.
- Protein hyperacetylation may be a marker of mitochondrial distress rather than a driver.
- Fatty-acid oxidation arguments are less compelling in dopaminergic neurons than ROS detoxification and calcium handling.
**Falsifying experiment**
- Test whether honokiol or other proposed activators still protect in SIRT3-null dopaminergic neurons, with readouts for SOD2 acetylation, IDH2 activity, NADPH/GSH balance, and mPTP opening.
- If protection persists without SIRT3, the mechanism is misassigned.
**Revised confidence**
- **0.46**
## Bottom line
The strongest mechanistic candidates here are:
1. **PARP1-NAD+-AIF bioenergetic collapse**
2. **Iron-lipid peroxidation-ferroptotic amplification**
3. **Microglial NOX2 inflammatory amplification**
The weakest aspect of the full set is that most hypotheses do not explicitly define a **closed feedback loop** of the form:
`ROS source -> molecular damage -> organelle/signaling failure -> death-program activation -> new ROS/iron/lipid radical generation -> more ROS`
The next step should be to reformulate them as **loop-native mechanistic hypotheses**, not therapy-first proposals. If you want, I can rewrite all six into sharper causal-loop hypotheses and rank them by falsifiability.